Sources of funding

All research carried out within the Women's Health Research Program in the School of Public Health and Preventive Medicine, Monash University, is approved by the Monash University Human Ethics Committee. As part of this approval process all sources of funding are clearly stated.

Sources of research funding

The main source of funding for the Women's Health Research Program is from the National Health and Medical Research Council (NHMRC) of Australia – Level 3 NHMRC Investigator Grant to Professor Susan Davis (2016627).

A single site, randomised, double-blind, placebo-controlled, cross over, 56-week Evaluating Testosterone Therapy to Prevent Heart Failure in Women: The ETHEL Study – Heart Foundation Vanguard Grant.

MenoPROMPT: a co-designed, comprehensive evidence-based program to improve the care of women at and after midlife – Partnership Project Grant (2015514).

Preventing bone loss and restoring sexual function in women at menopause: a randomized, double blind, placebo-controlled trial supported by the MRFF(2006143).

Optimising the health of women at midlife to minimise immediate and long-term morbidity – NHMRC Partnership Project Grant (1152778).

The Grollo Ruzzene Foundation Young Women’s Health Study is supported by a philanthropic grant from the Grollo Ruzzene Foundation.

Other sources of support

The Phase II, multicentre, double-blind, randomised, placebo-controlled trial to demonstrate the efficacy and safety of BP101 in patients with hypoactive sexual desire disorder is supported by Ovocabio.

Other financial disclosures: Susan Davis has received honoraria from Besins Healthcare, Abbott, Astellas, Gedeon Richter and Lawley Pharmaceuticals.